Compare ASPS & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASPS | IFRX |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | Luxembourg | Germany |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.0M | 60.6M |
| IPO Year | 2025 | 2017 |
| Metric | ASPS | IFRX |
|---|---|---|
| Price | $6.55 | $0.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 33.9K | ★ 294.7K |
| Earning Date | 03-04-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 112.00 | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $942,213,000.00 | N/A |
| Revenue This Year | N/A | $2,622.92 |
| Revenue Next Year | N/A | $120.74 |
| P/E Ratio | $45.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.65 | $0.71 |
| 52 Week High | $15.96 | $1.94 |
| Indicator | ASPS | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.67 | 38.37 |
| Support Level | $6.07 | $0.79 |
| Resistance Level | $7.33 | $0.91 |
| Average True Range (ATR) | 0.55 | 0.10 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 34.11 | 10.21 |
Altisource Portfolio Solutions SA is an integrated service provider and marketplace for the real estate and mortgage industries. It operates via two reportable segments, namely Servicer and Real Estate, which derive maximum revenue, and Origination. The Servicer and Real Estate segment provides loan servicers and real estate investors with solutions and technologies that span the mortgage and real estate lifecycle. The Origination segment provides originators with solutions and technologies that span the mortgage origination lifecycle. Altisource mainly serves financial institutions, government-sponsored enterprises, and originators in the United States, with the majority of its revenue flowing from field services and mortgage and real estate solutions.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.